You are here

  • Home
  • Archive
  • Volume 76, Issue 11
  • Perceived discrimination at work: examining social, health and work-related factors as determinants among breast cancer survivors – evidence from the prospective CANTO cohort

Article Text

Article menu
Download PDFPDF
Original research
Perceived discrimination at work: examining social, health and work-related factors as determinants among breast cancer survivors – evidence from the prospective CANTO cohort
  1. Garazi Ruiz De Azua1,
  2. Ines Vaz-Luis2,3,
  3. Thomas Bovagnet1,
  4. Antonio Di Meglio3,
  5. Julie Havas3,
  6. Elsa Caumette1,4,
  7. Elise Martin3,
  8. Barbara Pistilli5,
  9. Charles Coutant6,
  10. Paul Cottu7,
  11. Philippe Rouanet8,
  12. Antoine Arnaud9,
  13. Olivier Arsene10,
  14. Mahmoud Ibrahim11,
  15. Johanna Wassermann12,
  16. Roman Rouzier13,
  17. Anne-Laure Martin14,
  18. Sibille Everhard14,
  19. Agnes Dumas15,
  20. Gwenn Menvielle1
  1. 1 Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Équipe de Recherche en Épidémiologie Sociale, Sorbonne Universite, Paris 75012, France
  2. 2 Medical Oncology Department, Gustave Roussy Institute, Villejuif, France
  3. 3 INSERM Unit 981 - Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France
  4. 4 Department of Maieutics, Universite de Montpellier, Montpellier, France
  5. 5 Breast Cancer Group, Institut Gustave-Roussy, Villejuif, France
  6. 6 Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
  7. 7 Department of Medical Oncology, Institut Curie, Paris, France
  8. 8 Department of Medical Oncology, C.R.L.C Val d'Aurelle, Montpellier, France
  9. 9 Unité Onco Sein-Gynéco, Clinique Ste Catherine, Avignon, France
  10. 10 Centre de Coordination en Cancérologie, Centre Hospitalier de Blois, Blois, France
  11. 11 Hôpital de la Source, CHR, Orleans, France
  12. 12 Department of Medical Oncology, Pitié-Salpêtrière Hospital, APHP, Sorbonne Universite, Paris, France
  13. 13 Surgery, Institut Curie, Paris, France
  14. 14 UCBG, UNICANCER, Paris, France
  15. 15 Université Paris Cité, Inserm, ECEVE, UMR 1123, Paris, France
  1. Correspondence to Garazi Ruiz De Azua, Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Équipe de Recherche en Épidémiologie Sociale, Paris 75012, France, Paris 75012, France; garazi.ruizdeazua{at}iplesp.upmc.fr

Abstract

Background We assessed the prevalence of self-reported perceived discrimination in the workplace after the end of treatment among breast cancer (BC) survivors and studied its association with social, health-related and work-related factors.

Methods We used data from a French prospective cohort (CANcer TOxicities) including women diagnosed with stage I–III BC. Our analysis included 2130 women who were employed, <57 years old at BC diagnosis and were working 2 years afterwards. We assessed the association between social, health-related and work-related factors and perceived discrimination in the workplace using logistic regression models.

Results Overall, 26% of women reported perceived discrimination in the workplace after the end of treatment. Women working for a small company, in the public sector or with better overall health status were less likely to report perceived discrimination. Women who benefited from easing dispositions at their workplace, who did not feel supported by their colleagues and those who returned to work because of fear of job loss were more likely to report perceived discrimination.

Conclusions One in four BC survivors perceives discrimination in the workplace. Health and work-related factors are associated with increased likelihood of reporting perceived discrimination.

Trial registration number NCT01993498.

  • EPIDEMIOLOGY
  • PUBLIC HEALTH
  • LONGITUDINAL STUDIES
  • QUALITY OF LIFE

Data availability statement

Data may be obtained from a third party and are not publicly available. CANTO data are not publicly available and can be obtained from UNICANCER. La Vie Deux Ans Après Un Diagnostic de Cancer - 2012, INSERM, INCa (Producteurs), ADISP (Diffuseur) data are not publicly available and can be obtained from Quetelet PROGEDO.

https://doi.org/10.1136/jech-2021-218331

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data may be obtained from a third party and are not publicly available. CANTO data are not publicly available and can be obtained from UNICANCER. La Vie Deux Ans Après Un Diagnostic de Cancer - 2012, INSERM, INCa (Producteurs), ADISP (Diffuseur) data are not publicly available and can be obtained from Quetelet PROGEDO.

    View Full Text

    Footnotes

    • Contributors Conception and design: GRDA and GM. Administrative support: SE and A-LM. Provision of study material or patients: BP, CC, PC, PR, AA, OA, MI, JW and RR. Collection and assembly of data: IV-L, TB, ADM, JH, AD and GM. Data analysis and interpretation: GRDA, GM, IV-L, ADM, EC and AD. Manuscript writing: all authors. Final approval of manuscript: all authors. Accountable for all aspects of the work: all authors. Guarantor: GM

    • Funding The authors of this paper thank Quetelet PROGEDO for sharing their data. This research was supported by the French Government under the 'Investment for the Future' programme managed by the National Research Agency (ANR), grant n° ANR-10-COHO-0004 and ARC (number PGA1 RF20170205420).

    • Competing interests BP: consulting/advisor: Puma Biotechnology, Novartis, Myriad Genetics and Pierre Fabre; personal fees: Novartis, AstraZeneca, MSD Oncology and Pfizer; research funding: Daiichi, Puma Biotechnology, Novartis, Merus, Pfizer and AstraZeneca.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.